← Back to Search

Cannabinoid

CBG + THC for Pain (ASCENT Trial)

Phase 1
Recruiting
Led By Ziva D Cooper, PhD
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or non-pregnant and non-lactating females aged 21-55 years
Male or non-pregnant and non-lactating females aged 21-55 years
Must not have
Current pain
History of respiratory illness or current respiratory illness
Timeline
Screening 1 day
Treatment 2 months
Follow Up 7 hours

Summary

This trial will study the effects of the cannabis compound CBG by itself and combined with THC. They will measure pain relief, appetite, and other subjective effects.

Who is the study for?
The ASCENT trial is for men and non-pregnant, non-lactating women aged 21-55 who occasionally use cannabis but aren't seeking treatment for it. Participants must have a BMI of 18.5 - 34kg/m2 and agree to use contraception. Excluded are those with moderate-severe substance disorders (except mild Cannabis Use Disorder), certain mental health conditions, significant illnesses, current pain issues, or respiratory diseases.
What is being tested?
This study examines the effects of cannabigerol (CBG) alone and combined with THC on pain relief and appetite stimulation. It involves different doses: high THC, low CBG, high CBG, low THC, and placebo to compare their impacts in a controlled environment.
What are the potential side effects?
Potential side effects may include typical reactions associated with cannabis such as changes in mood or perception, dry mouth, increased heart rate, red eyes, coordination difficulties or dizziness. The severity can vary based on individual response to THC/CBG.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a man or a woman not pregnant or breastfeeding, aged 21-55.
Select...
I am a man or a woman not pregnant or breastfeeding, aged 21-55.
Select...
I am not currently breastfeeding.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am experiencing pain.
Select...
I have or had a lung or breathing problem.

Timeline

Screening ~ 1 day
Treatment ~ 2 months
Follow Up ~7 hours
This trial's timeline: 1 day for screening, 2 months for treatment, and 7 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Abuse liability
Analgesia
Appetite stimulation
Secondary study objectives
Subjective ratings of intoxication
Subjective ratings of pain

Trial Design

9Treatment groups
Active Control
Placebo Group
Group I: Low strength CBG + High strength THCActive Control2 Interventions
5 mg CBG + 15 mg THC
Group II: High strength THCActive Control1 Intervention
0 mg CBG, 30 mg THC
Group III: High strength CBG + Low strength THCActive Control2 Interventions
15 mg CBG + 5 mg THC
Group IV: High strength CBGActive Control1 Intervention
15 mg CBG, 0 mg THC
Group V: Low strength CBG + Low strength THCActive Control2 Interventions
5 mg CBG + 5 mg THC
Group VI: Low strength THCActive Control1 Intervention
0 mg CBG, 5 mg THC
Group VII: Low strength CBGActive Control1 Intervention
5 mg CBG, 0 mg THC
Group VIII: High strength CBG + High strength THCActive Control2 Interventions
15 mg CBG + 15 mg THC
Group IX: PlaceboPlacebo Group1 Intervention
0 mg CBG, 0 mg THC

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,569 Previous Clinical Trials
10,314,275 Total Patients Enrolled
9 Trials studying Pain
1,382 Patients Enrolled for Pain
Center for Medicinal Cannabis ResearchOTHER
18 Previous Clinical Trials
609 Total Patients Enrolled
2 Trials studying Pain
32 Patients Enrolled for Pain
Ziva D Cooper, PhDPrincipal InvestigatorUniversity of California, Los Angeles
1 Previous Clinical Trials
18 Total Patients Enrolled
1 Trials studying Pain
18 Patients Enrolled for Pain

Media Library

Cannabigerol (CBG) (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT04859296 — Phase 1
Pain Research Study Groups: Low strength CBG + High strength THC, High strength THC, High strength CBG + Low strength THC, High strength CBG, Low strength CBG + Low strength THC, Low strength THC, Placebo, Low strength CBG, High strength CBG + High strength THC
Pain Clinical Trial 2023: Cannabigerol (CBG) Highlights & Side Effects. Trial Name: NCT04859296 — Phase 1
Cannabigerol (CBG) (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04859296 — Phase 1
Pain Patient Testimony for trial: Trial Name: NCT04859296 — Phase 1
~4 spots leftby Jun 2025